• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

NightWare Awarded FDA “Breakthrough Status” for PTSD Apple Watch App

by Jasmine Pennic 05/24/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

 NightWare Awarded FDA "Breakthrough Status" for PTSD Apple Watch App

NightWare, Inc., digital therapeutics for mental health company has received Breakthrough Status designation from the U.S. Food and Drug Administration (FDA) for its NightWare Apple Watch app that measures and treats nightmares in people with Post-Traumatic Stress Disorder (PTSD).

Impact of Nightmare Disorders

Nightmares and Nightmare Disorder have been linked to increased suicidality, heightened risk of heart disease, diabetes, and contributes to cognitive difficulties such as memory loss, anxiety, depression and other physical and mental conditions. It is estimated that nearly 5 million Americans suffer from Nightmare Disorder in the U.S. each year through referencing PTSD diagnoses and CDC data relating to PTSD.

What is NightWare?

NightWare is a smartwatch application that runs on the Apple Watch platform. The device collects biometric data through integrated sensors and uses machine learning algorithms to create a profile of an individual’s sleep patterns. At the point the onset of a nightmare is detected, the device intervenes using vibrotactile feedback to arouse the sleeper out of sleep without waking them. The result is that the nightmare is interrupted without interrupting the circadian sleep pattern, enabling the patient to get better and more restful sleep.

Significance of FDA “Breakthrough Status”

This FDA designation recognizes a therapeutic solution for a life-threatening condition for which no currently approved treatment offers similar benefits to those of the proposed therapy. The designation allows the FDA to grant priority review when preliminary clinical trials indicate that a given therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases.

“This is truly a watershed moment for our company,” said NightWare CEO and Founder Grady Hannah. “In our initial studies, NightWare has demonstrated substantial and significant efficacy.

The FDA’s Breakthrough Status designation will enable us to complete our Randomized Clinical Trials ahead of schedule and give us the opportunity to help improve the lives of veterans and others suffering from PTSD sooner than we anticipated.”  Hannah added, “Our team is humbled and excited by this FDA designation.”

NightWare is currently enrolling patients in two Randomized Clinical Trials (RCTs), one of which is being conducted at VA hospitals in Minneapolis and St Cloud, Minnesota. The company is also enrolling a virtual RCT trial that is much broader in geographic scope.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: algorithms, apple, Apple Watch, Apple Watch App, Biometric Data, Clinical Trials, cloud, Depression, diabetes, Digital Therapeutics, FDA, Heart, heart disease, Machine Learning, Mental Health, Mental Health Apps, Mental Health Startups, NightWare, risk, sensors, Smartwatch

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |